Luca Richeldi.

The clinical protocol was approved by an unbiased ethics institutional or committee examine board at each participating center. All individuals provided written educated consent before study entry. All of the authors were involved in the design of the study and had usage of the data, that have been analyzed by the scholarly research sponsor, Boehringer Ingelheim. All the authors vouch for the precision and completeness of the info analyses and the fidelity of every study to the process. The process and statistical analysis plans can be found at The manuscript was drafted by the initial, second, and last authors and revised by all the authors. Medical writing assistance, payed for by Boehringer Ingelheim, was supplied by the Fleishman-Hillard Group.Dickson of the University of Kentucky University of Medication, who nominated Hannun for the award. ‘Indeed, their very name derives from the Greek sphinx, because they presented an enigma to their discoverer, Johann Thudicum. Dr. Hannun’s work has pioneered the way in deciphering this enigma by establishing the field of bioactive sphingolipids.’ Hannun gives his award lecture, titled ‘Network of Bioactive Sphingolipids,’ at 8:30 a.m. Mon, April 11, in the convention center’s Ballroom C, on the third level. The award includes a plaque, a $3,000 cash prize and travel expenses. Fritz Lipmann Lectureship Arthur E. Johnson, a distinguished professor at the Texas A&M Health Research Center’s College of Medication, gained the Fritz Lipmann Lectureship. The award, issued almost every other year, was established by friends and co-workers of Nobel Prize winner Lipmann for conceptual developments in biochemistry, bioenergetics or molecular biology.